CD274 and melanoma: In a clinical cohort of 30 melanoma patients, high tsMHC-II expression was associated with improved response rates to anti-PD-1/PDL1 immunotherapy and enhanced survival benefits, demonstrating superior predictive efficacy for immunotherapy response compared to PD-L1 [25].